InflaRx N.V.(IFRX)Earnings, Financials & Key Ratios
IFRX•NASDAQ
$1.92
Price updated Jun 27, 2026
AboutInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Show more
- Revenue$28K-83.0%
- EBITDA-$49M+7.7%
- Net Income-$44M+4.8%
- EPS (Diluted)-0.66+15.4%
- Gross Margin-26108.47%-1273.6%
- EBITDA Margin-172163.84%-443.4%
- Operating Margin-173594.03%-442.9%
- Net Margin-155584.2%-460.0%
- ROE-85.15%-51.6%
IFRX Price & Volume
InflaRx N.V. (IFRX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Liquidity Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- InflaRx faces a precarious fundamental outlook characterized by a lack of sustainable commercial revenue and a reliance on external capital to fund its clinical pipeline.
- The company's inability to generate positive operating income, evidenced by a $7.0 million operating loss in 2026Q1, necessitates ongoing scrutiny regarding its long-term solvency.
- Investors should remain cautious as the rapid erosion of the asset base and the absence of a scalable commercial model suggest significant risks of further dilutive financing.
Verdict Logic
the company's cash position has dwindled to $15.0 million as of 2026Q1, creating an imminent liquidity risk that likely necessitates further dilutive equity issuance to sustain operations.
IFRX Growth Metrics
InflaRx N.V. (IFRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-78.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.58%
Return on Capital
10 Years-51.21%
5 Years-64.42%
3 Years-68.25%
Last Year-93.99%
IFRX Recent Earnings
InflaRx N.V. (IFRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.09+47.1%
$0.17
Rev
—
$9,012
Q2 2026
May 6, 2026Metric
Actual
Est
EPS
$0.09+47.1%
$0.17
Rev
—
$9,012
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.17+5.6%
$0.18
Rev
$17,618-164.5%
$27,307
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.16+0.0%
$0.16
Rev
$27,910+6.7%
$26,170
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.09vs $0.17+47.1% | —vs $9,012 |
| Q2 2026 | May 6, 2026 | $0.09vs $0.17+47.1% | —vs $9,012 |
| Q2 2026 | Mar 19, 2026 | $0.17vs $0.18+5.6% | $17,618vs $27,307-164.5% |
| Q4 2025 | Nov 10, 2025 | $0.16vs $0.16+0.0% | $27,910vs $26,170+6.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for InflaRx N.V. (IFRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.92 | $138.8M | -2.55 | -83.01% | -155584.2% | -85.15% | — | |
| $887.18 | $54.9B | 45.20 | 89.64% | 32.14% | 24.93% | — | |
| $111.99 | $5.41B | 17.74 | 5.91% | 32.63% | 49.18% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $38.04 | $4.41B | -11.92 | — | — | -71.31% | — | |
| $2.04 | $110.62M | -1.07 | — | — | -124.06% | — |
Compare IFRX vs Peers
InflaRx N.V. (IFRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when IFRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IFRX Frequently Asked Questions
InflaRx N.V. (IFRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is InflaRx N.V.'s revenue?
InflaRx N.V. (IFRX) reported $0.0M in revenue for fiscal year 2025.
How fast is InflaRx N.V. growing?
InflaRx N.V. (IFRX) saw revenue decline by 83.0% over the past year.
Is IFRX profitable?
InflaRx N.V. (IFRX) reported a net loss of $41.2M for fiscal year 2025.
Dividend & Returns
What is IFRX's return on equity?
InflaRx N.V. (IFRX) has a return on equity (ROE) of -85.1%. Negative ROE indicates the company is unprofitable.
What is InflaRx N.V.'s free cash flow?
InflaRx N.V. (IFRX) had negative free cash flow of $28.9M in fiscal year 2025, likely due to heavy capital investments.